Purine and lipid metabolism in rats with a rotenone model of Parkinson’s disease under the influence of methanindiazenone

This study aims to evaluate the effect of methanindiazenone (МD), a new benzodiazepine derivative, on the levels of purine metabolites and lipids in the blood plasma of rats with rotenone (ROT) induced Parkinson’s disease (PD). The concentrations of ATP, ADP, AMP, xanthine, hypoxanthine, phospholipids (PL), cholesterol (CHOL), cholesterol esters (ECHOL), free fatty acids (FFA), and triglycerides (TG) were quantified in plasma samples by thin-layer chromatography. Our data demonstrate that in rats with ROT-induced PD the AMP/ATP ratio in plasma increased by 2.5 times compared to the control, and this indicator returned to normal values under the influence of MD. ROT also increased the concentration of xanthine and hypoxanthine by 26.7% (Р < 0.001) and 42.4% (Р < 0.001), respectively, compared to the control. MD restored xanthine concentration to 86.7% of the control level and returned hypoxanthine concentration to normal values. Besides, ROT reduced the blood plasma concentrations of PL, CHOL, ECHOL, FFA, TG by 22%, (Р < 0.001), 18% (Р < 0.001), 25% (Р < 0.001), 28% (Р < 0.001), 33% (Р < 0.001), respectively. Under the influence of MD, such indicators as the blood plasma concentration of PL, CHOL, FFA returned to control levels. Оur results suggest that MD improves the metabolism of both purines and lipids in rats with ROT-induced PD.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  N. D’ascenzo,et al.  Metabolomics of blood reveals age-dependent pathways in Parkinson’s Disease , 2022, Cell & bioscience.

[3]  Wenting Guo,et al.  Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson's Disease: A Meta-Analysis and Systematic Review , 2022, International journal of clinical practice.

[4]  M. Kameyama,et al.  Ca2+ Dyshomeostasis Links Risk Factors to Neurodegeneration in Parkinson’s Disease , 2022, Frontiers in Cellular Neuroscience.

[5]  B. Popescu,et al.  Serum Uric Acid Levels in Parkinson’s Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania , 2022, Medicina.

[6]  J. Lavandera,et al.  1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents , 2021, Antioxidants.

[7]  O. Tsymbalyuk,et al.  Corrective effects of benzodiazepine derivative – diazepinone on purine and lipid metabolism in the liver of rats with Parkinson’s disease , 2021, Fiziolohichnyĭ zhurnal.

[8]  E. Simonsick,et al.  Blood Cholesterol Decreases as Parkinson's Disease Develops and Progresses. , 2021, Journal of Parkinson's disease.

[9]  M. Maiuri,et al.  Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease , 2020, Aging.

[10]  M. Mattson,et al.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing , 2020, Nature Reviews Drug Discovery.

[11]  Xiangyang Zhang,et al.  A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease , 2020, Lipids in Health and Disease.

[12]  M. M. Gromiha,et al.  Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause? , 2020, Frontiers in Neuroscience.

[13]  M. Okun,et al.  Diagnosis and Treatment of Parkinson Disease: A Review. , 2020, JAMA.

[14]  I. Komarov,et al.  Corvitin modulates the content of lipids in rat liver bile , 2019 .

[15]  C. Sue,et al.  New insights into the complex role of mitochondria in Parkinson’s disease , 2019, Progress in Neurobiology.

[16]  S. Costa,et al.  JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson’s disease , 2019, Neuroscience Letters.

[17]  B. Wieringa,et al.  The Role of Lipids in Parkinson’s Disease , 2019, Cells.

[18]  V. Moskvina,et al.  Interaction of 3-pyridyland 3-(imidazo[1,2-a]pyridin-2-yl)isocoumarins with hydrazine , 2018, Natsional'na Akademiya Nauk Ukrainy. Dopovidi: naukovyi zhurnal.

[19]  Yves Dauvilliers,et al.  REM sleep behaviour disorder , 2018, Nature Reviews Disease Primers.

[20]  Xiansi Zeng,et al.  Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment , 2018, ASN neuro.

[21]  Martin D. Brand,et al.  The Role of Mitochondrially Derived ATP in Synaptic Vesicle Recycling*♦ , 2015, The Journal of Biological Chemistry.

[22]  M. Amiji,et al.  Mitochondrial biology, targets, and drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[23]  D. Souza,et al.  Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: Mitoprotection against Ca2+-induced mitochondrial impairment , 2014, Brain Research Bulletin.

[24]  Robert Powers,et al.  Alterations in Energy/Redox Metabolism Induced by Mitochondrial and Environmental Toxins: A Specific Role for Glucose-6-Phosphate-Dehydrogenase and the Pentose Phosphate Pathway in Paraquat Toxicity , 2014, ACS chemical biology.

[25]  A. Milici,et al.  Human A53T α-Synuclein Causes Reversible Deficits in Mitochondrial Function and Dynamics in Primary Mouse Cortical Neurons , 2013, PloS one.

[26]  Pravir Kumar,et al.  Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat , 2012, Neuroscience.

[27]  P. Pinton,et al.  ATP synthesis and storage , 2012, Purinergic Signalling.

[28]  U. Saxena.  Bioenergetics failure in neurodegenerative diseases: back to the future , 2012, Expert opinion on therapeutic targets.

[29]  Xianlin Han,et al.  Neuronal LRP1 Knockout in Adult Mice Leads to Impaired Brain Lipid Metabolism and Progressive, Age-Dependent Synapse Loss and Neurodegeneration , 2010, The Journal of Neuroscience.

[30]  M. Kivipelto,et al.  Total cholesterol and the risk of Parkinson disease , 2008, Neurology.

[31]  A. Fasano,et al.  Gastrointestinal dysfunction in Parkinson's disease , 2003, The Lancet Neurology.

[32]  L. Horrocks,et al.  Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. , 2000, Chemistry and physics of lipids.

[33]  J. Fritschy,et al.  A new benzodiazepine pharmacology. , 2002, The Journal of pharmacology and experimental therapeutics.